To understand why erythritol poses unique cardiovascular risks, we need to examine how the body processes it or more accurately, doesn't process it.
Absorption and Metabolism
Erythritol has unusual pharmacokinetic properties:
- 90% absorption in the small intestine - much higher than other sugar alcohols like xylitol (~50%) or sorbitol (~25%)
- No metabolism - erythritol is not broken down by human enzymes and passes through the body unchanged
- Renal excretion only - elimination depends entirely on kidney function
The Critical Problem: Long Plasma Half-Life
Erythritol's plasma half-life is approximately 24 hours. This means:
- After 24 hours, half the erythritol consumed is still circulating in your bloodstream
- After 48 hours, 25% remains
- After 72 hours, 12.5% remains
For people who consume erythritol daily (morning coffee, afternoon snack, evening dessert), this creates a bioaccumulation effect plasma levels never return to baseline, progressively increasing with each consumption.
Peak Plasma Concentrations
The 2024 intervention study found that a single 30g dose of erythritol produces peak plasma concentrations of ~500 µM (micromolar). This is critical because:
- Platelet activation begins at concentrations as low as 0.1 mM (100 µM)
- Typical erythritol consumption easily exceeds this threshold
- The effect is dose-dependent higher concentrations produce stronger platelet activation